RU2381234C2 - Антитела и родственные молекулы, связывающиеся с белками psca - Google Patents

Антитела и родственные молекулы, связывающиеся с белками psca Download PDF

Info

Publication number
RU2381234C2
RU2381234C2 RU2006146666/13A RU2006146666A RU2381234C2 RU 2381234 C2 RU2381234 C2 RU 2381234C2 RU 2006146666/13 A RU2006146666/13 A RU 2006146666/13A RU 2006146666 A RU2006146666 A RU 2006146666A RU 2381234 C2 RU2381234 C2 RU 2381234C2
Authority
RU
Russia
Prior art keywords
seq
antibody
pta
sequence
fragment
Prior art date
Application number
RU2006146666/13A
Other languages
English (en)
Russian (ru)
Other versions
RU2006146666A (ru
Inventor
Жан ГУДАС (US)
Жан Гудас
Ая ДЖЕЙКОБОВИТЦ (US)
Ая Джейкобовитц
Ксяо-чи ДЗИА (US)
Ксяо-Чи ДЗИА
Роберт Кендол МОРРИСОН (US)
Роберт Кендол Моррисон
Карен Джейн Мейрик МОРРИСОН (US)
Карен Джейн Мейрик Моррисон
Хуи САО (US)
Хуи САО
Пиа М. ЧАЛЛИТА-ЭИД (US)
Пиа М. ЧАЛЛИТА-ЭИД
Артур Б. РАИТАНО (US)
Артур Б. РАИТАНО
Original Assignee
Эдженсис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/017231 external-priority patent/WO2005014780A2/en
Application filed by Эдженсис, Инк. filed Critical Эдженсис, Инк.
Publication of RU2006146666A publication Critical patent/RU2006146666A/ru
Application granted granted Critical
Publication of RU2381234C2 publication Critical patent/RU2381234C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2006146666/13A 2004-05-28 2005-05-17 Антитела и родственные молекулы, связывающиеся с белками psca RU2381234C2 (ru)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
PCT/US2004/017231 WO2005014780A2 (en) 2003-05-30 2004-05-28 Prostate stem cell antigen (psca) variants and subsequences thereof
USPCT/US2004/017231 2004-05-28
US10/857,484 2004-05-28
US10/857,484 US7622564B2 (en) 2003-05-30 2004-05-28 Prostate stem cell antigen (PSCA) variants and subsequences thereof
US61638104P 2004-10-05 2004-10-05
US60/616,381 2004-10-05
US61788104P 2004-10-12 2004-10-12
US60/617,881 2004-10-12
US62131004P 2004-10-21 2004-10-21
US60/621,310 2004-10-21
US63307704P 2004-12-02 2004-12-02
US60/633,077 2004-12-02
US67200005P 2005-04-14 2005-04-14
US60/672,000 2005-04-14
PCT/US2005/017412 WO2005118864A2 (en) 2004-05-28 2005-05-17 Antibodies and related molecules that bind to psca proteins

Publications (2)

Publication Number Publication Date
RU2006146666A RU2006146666A (ru) 2008-07-10
RU2381234C2 true RU2381234C2 (ru) 2010-02-10

Family

ID=35463465

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006146666/13A RU2381234C2 (ru) 2004-05-28 2005-05-17 Антитела и родственные молекулы, связывающиеся с белками psca

Country Status (11)

Country Link
EP (3) EP2583981A3 (enExample)
JP (1) JP4651663B2 (enExample)
AU (1) AU2005250370B2 (enExample)
CA (1) CA2567449C (enExample)
IL (1) IL179332A (enExample)
MX (1) MXPA06013834A (enExample)
NO (1) NO338744B1 (enExample)
NZ (1) NZ551627A (enExample)
PL (1) PL1753871T3 (enExample)
RU (1) RU2381234C2 (enExample)
WO (1) WO2005118864A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2632647C2 (ru) * 2011-04-22 2017-10-06 Аптево Рисерч Энд Девелопмент Ллс Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы
RU2759879C2 (ru) * 2015-10-06 2021-11-18 Сити Оф Хоуп Химерные рецепторы антигена, нацеленные на psca

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1629088T3 (da) * 2003-05-30 2012-05-07 Agensys Inc Varianter af prostatastamcelleantigen (psca) og undersekvenser deraf
WO2006112933A1 (en) * 2005-04-14 2006-10-26 Agensys, Inc. Antibodies and related molecules that bind to psca proteins
WO2008029807A1 (fr) * 2006-09-06 2008-03-13 Japan Science And Technology Agency Nouveau polypeptide ayant une cytotoxicité contre le cancer, procédé pour cribler le polypeptide et utilisation du polypeptide
EP1970441A1 (en) * 2007-03-06 2008-09-17 BioAlliance Pharma Plasmid containing a sequence encoding a disintegrin domain of metargidin (RDD)
CA2703140A1 (en) * 2007-10-25 2009-04-30 Viventia Biotech Inc. Antibodies against a cancer-associated epitope of variant hnrnpg and uses thereof
US20120004289A1 (en) * 2009-03-06 2012-01-05 The Johns Hopkins University Annexin a11 and associated genes as biomarkers for cancer
CA2810668A1 (en) * 2010-09-08 2012-03-15 Halozyme, Inc. Methods for assessing and identifying or evolving conditionally active therapeutic proteins
DE102011118022B4 (de) * 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
HK1213481A1 (zh) 2012-12-13 2016-07-08 The Trustees Of The University Of Pennsylvania Dna抗体构建体及其使用方法
CN105829341A (zh) 2013-12-13 2016-08-03 宾夕法尼亚大学理事会 Dna抗体构建体及其使用方法
CN107427566B (zh) 2014-12-01 2021-08-17 宾夕法尼亚大学理事会 Dna抗体构建体及其使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040403A1 (en) * 1997-03-10 1998-09-17 The Regents Of The University Of California Psca: prostate stem cell antigen

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5359100A (en) 1987-10-15 1994-10-25 Chiron Corporation Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US5254678A (en) 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
CA2049028A1 (en) 1989-03-07 1990-09-08 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
DE69031305T2 (de) 1989-11-03 1998-03-26 Univ Vanderbilt Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
JP3179481B2 (ja) 1990-06-27 2001-06-25 プリンストン ユニバーシティ 突然変異体ｐ５３検出用プローブ
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
SE9002480D0 (sv) 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
AU4528493A (en) 1992-06-04 1994-01-04 Regents Of The University Of California, The In vivo gene therapy with intron-free sequence of interest
ATE342730T1 (de) 1992-08-07 2006-11-15 Pharmexa Inc Hla bindepeptide und ihre verwendungen
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
DE69314148T2 (de) 1992-12-17 1998-01-15 Valeo Systemes Essuyage Stromversorgungsverfahren und -vorrichtung für einen elektrischen Motor zum Antrieb eines Scheibenwischers eines Kraftfahrzeugs
US5576220A (en) 1993-02-19 1996-11-19 Arris Pharmaceutical Corporation Thin film HPMP matrix systems and methods for constructing and displaying ligands
WO1994020127A1 (en) 1993-03-05 1994-09-15 Cytel Corporation Hla-a2.1 binding peptides and their uses
AU680921B2 (en) 1993-05-17 1997-08-14 Regents Of The University Of California, The Ribozyme gene therapy for HIV infection and AIDS
US5837501A (en) 1993-07-09 1998-11-17 Akzo Nobel N.V. Nucleic acid quantitation by co-amplification of target with multiple internal controls
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
EP0735893B1 (en) 1993-09-14 2008-11-26 Pharmexa Inc. Pan dr-binding peptides for enhancement of the immune response
US5681697A (en) 1993-12-08 1997-10-28 Chiron Corporation Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor
CH686982A5 (fr) 1993-12-16 1996-08-15 Maurice Stroun Méthode pour le diagnostic de cancers.
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
EP0773952B1 (en) 1994-07-20 2003-11-12 The General Hospital Corporation Interaction trap systems for detecting protein interactions
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5681702A (en) 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
CA2217545A1 (en) 1995-04-11 1996-10-17 Marc Vidal Reverse two-hybrid systems
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US5585639A (en) 1995-07-27 1996-12-17 Hewlett-Packard Company Optical scanning apparatus
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
ATE511849T1 (de) 1996-03-11 2011-06-15 Epimmune Inc Peptide mit erhöhter bindungsaffinität für mindestens drei hla-a3-ähnliche moleküle
US5928868A (en) 1996-04-26 1999-07-27 Massachusetts Institute Of Technology Three hybrid screening assay
US6294378B1 (en) 1996-07-26 2001-09-25 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
DE69738077T2 (de) 1996-10-15 2008-05-21 The Regents Of The University Of California, Oakland Tiermodelle für die menschliche prostatakrebsfortschreitung
US6365797B1 (en) 1997-10-15 2002-04-02 The Regents Of The University Of California Mice models of human prostate cancer progression
US5846722A (en) 1996-10-16 1998-12-08 Terrapin Technologies, Inc. System to detect small molecule/peptide interaction
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6541212B2 (en) * 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
US6258939B1 (en) * 1997-03-10 2001-07-10 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
DK1226177T3 (da) * 1999-10-29 2008-10-06 Genentech Inc Antistofsammensætninger mod anti-prostata stamcelle-antigen (PSCA) og anvendelser deraf
US6407588B1 (en) 2000-08-28 2002-06-18 Micron Technology, Inc. High speed low power input buffer
DK1354034T3 (da) 2000-11-30 2008-03-25 Medarex Inc Transgene transchromosomale gnavere til fremstilling af humane antistoffer
WO2006112933A1 (en) * 2005-04-14 2006-10-26 Agensys, Inc. Antibodies and related molecules that bind to psca proteins
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
WO2013037693A2 (de) 2011-09-15 2013-03-21 Convergent Information Technologies Gmbh System und verfahren zur automatisierten erstellung von roboterprogrammen
EP2514876A1 (en) * 2012-05-03 2012-10-24 Tata Steel UK Ltd Safety fence and post for safety fence
US9804664B2 (en) 2014-05-27 2017-10-31 Qualcomm Incorporated Adaptive control of RF low power modes in a multi-rate wireless system using MCS value
US9679613B1 (en) 2016-05-06 2017-06-13 Invensas Corporation TFD I/O partition for high-speed, high-density applications

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040403A1 (en) * 1997-03-10 1998-09-17 The Regents Of The University Of California Psca: prostate stem cell antigen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUFFRAN D.C. ET AL. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proceedings Nat′l Acad. Sci. February 2001, Vol.98, No.5, pages 2658-2663. РОЙТ А. и др. Иммунология. - M.: Мир, 2000, с.97-114. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2632647C2 (ru) * 2011-04-22 2017-10-06 Аптево Рисерч Энд Девелопмент Ллс Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы
RU2759879C2 (ru) * 2015-10-06 2021-11-18 Сити Оф Хоуп Химерные рецепторы антигена, нацеленные на psca
US11466097B2 (en) 2015-10-06 2022-10-11 City Of Hope Chimeric antigen receptors targeted to PSCA

Also Published As

Publication number Publication date
CA2567449A1 (en) 2005-12-15
EP2428522A1 (en) 2012-03-14
MXPA06013834A (es) 2007-03-01
IL179332A (en) 2012-10-31
IL179332A0 (en) 2007-03-08
CA2567449C (en) 2014-03-11
JP2008500833A (ja) 2008-01-17
WO2005118864A3 (en) 2006-02-09
PL1753871T3 (pl) 2016-01-29
EP1753871A2 (en) 2007-02-21
EP1753871B1 (en) 2015-07-15
AU2005250370B2 (en) 2010-04-01
NO338744B1 (no) 2016-10-17
EP2583981A2 (en) 2013-04-24
RU2006146666A (ru) 2008-07-10
EP2583981A3 (en) 2013-07-31
NZ551627A (en) 2010-02-26
EP1753871A4 (en) 2009-05-27
JP4651663B2 (ja) 2011-03-16
WO2005118864A2 (en) 2005-12-15
NO20065874L (no) 2006-12-19
AU2005250370A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
US9765136B2 (en) Modulators and methods of use
KR102022734B1 (ko) 신규 조절제 및 용법
RU2381234C2 (ru) Антитела и родственные молекулы, связывающиеся с белками psca
HRP20140171T1 (hr) Protutijela i od njih izvedene molekule koje se vežu na steap-1-proteine
JP2010537671A5 (enExample)
US20200255536A1 (en) Target for b-cell disorders
RU2007140311A (ru) Антитела и родственные молекулы, связываюшиеся с белками 161p2f10b
CN119013305A (zh) 靶向gpc3的单克隆抗体和包含此抗体的抗体药物缀合物
WO2024001669A9 (zh) 靶向itga2的抗体和包含此抗体的抗体药物缀合物
CN118515777A (zh) 双价或多价抗体的构建体、其建立方法及应用
KR101364172B1 (ko) 원숭이 ｃｄ４３에 특이적인 단일클론항체 및 이를 생산하는 융합세포주
CN120424221B (zh) 靶向德曲妥珠单抗的抗体及其用途
CN114478779B (zh) 人源化的磷脂酰肌醇蛋白聚糖3的单克隆抗体及其应用
KR102090407B1 (ko) 항-icam4 항체 및 icam4 발현 세포와 관련된 질병의 진단 및 치료용 조성물
TW201800420A (zh) 抗ascl1抗體及使用方法
WO2025188810A1 (en) Anti-human pax8 antibody for in vitro diagnostic use by immunohistochemistry
KR101650046B1 (ko) 영장류 cd19에 특이적인 항체 및 이를 생산하는 융합세포주
WO2025191017A1 (en) Megalin-targeting drug conjugates for treatment of cancers
CA3186062A1 (en) Cell surface mica and micb detection using antibodies
KR20110024037A (ko) 원숭이 ｃｄ4에 특이적인 단일클론항체 및 이를 생산하는 융합세포주